Topical steroids as alternative to systemic hormonal treatment for inflammatory bowel diseases in pediatric practice

The aim of review. To share experience of application of topical steroids (Budenofalk®) in children with hormone – dependent inflammatory bowel diseases (IBD) and severe side effects on a background of systemic corticosteroids (CS).

Original positions. Etiopathogenesis of IBD represents the cascade of self-maintaining pathophysiological reactions: adaptive microcirculational, hypoxicmetabolic, autoimmune inflammatory and dysbiotic disorders emerging on a background of genetic features of the body under the effect of unfavorable environmental factors. Anti-inflammatory treatment aimed to destruction of «vicious circle» of inflammatory responses occupies the main place in the treatment of IBD. CS are agents of choice of the second line. Prescription of CS is indicated at high severity of disease, active extraintestinal manifestations, absence of response to 5-aminosalicylic acid or dangerous side effects. At the same time CS application is associated to high risk of side effects and complications caused by their systemic action, and hormone-dependence. Introduction of topical steroids (Budenofalk®) to IBD treatment in some cases allows to resolve these problems. Experience of topical steroids application in the treatment of IBD in pediatrics is rather limited. On the basis of the Nizhny Novgorod scientific research institute of pediatric gastroenterology Budenofalk® was applied in 5 cases of IBD with severe cushingoid syndrome on a background of systemic CS and/or hormone-dependent course of disease to overcome dependency for CS and decrease of steroidrelated side effects. The article presents description of clinical case of successful application of budesonide according to determined goal.

Conclusion. Budenofalk® can be a drug of choice in patients with hormone-dependent IBD, and at high risk of complications and severe side effects of systemic CS. 

1. Корниенко Е.А., Ломакина Е.А., Залетова Н.К., Фадина С.А. Возможности системных и топических стероидов в лечении воспалительных заболеваний кишечника у детей // Мед. науч.-практ. журн. «Лечащий врач». – 2010. – № 4. – С. 82–85.

2. Кушнир И.Э. Воспалительные заболевания кишечника: диагностика и лечение // Искусство лечения. Мистецтво лікування. – 2005. – № 3 (19). – С. 11–15.

3. Ситкин С.И. Топические кортикостероиды в терапии воспалительных заболеваний кишечника // Фарматека. – 2008. – № 13 (167). – С. 84–89.

4. Ситкин С.И., Жигалова Т.Н., Ткаченко Е.И. Применение топических кортикостероидов при болезни Крона и язвенном колите // Гастроэнтерология СанктПетербурга. – 2008. – № 4. – С. 2–6.

5. Федулова Э.Н., Тутина О.А., Федорова О.В. и др. Язвенный колит и болезнь Крона у детей: новые подходы к лечению // Мед. альманах. – 2008. – № 5. – С. 160–163.

6. Bar-Meir S., Chowers Y., Lavy A. et al. Budesonide versus prednisone in the treatment of active Crohn‘s disease // Gastroenterology. – 1998. – Vol. 115, N 4. – P. 835–840.

7. Barnes P.J., Adcock I.M. How do corticosteroids work in asthma? // Ann. Intern. Med. – 2003. – Vol. 139 (suppl. 5, pt. 1). – P. 359–370.

8. Brattsand R. Steroid development: a case of enhanced selectivity for the bowel wall // Res. Clin. Forums. – 1993. – Vol. 15. – P. 17–31.

9. Dilger K., Alberer M., Busch A. et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn disease // Aliment. Pharmacol. Ther. – 2006. – Vol. 23, N 3. – P. 387–396.

10. Hochhaus G., Derendorf H., Mollmann H.W. et al. Pharmacodynamic aspects of glucocorticoid action. – Dordrecht: Kluwer Academic Publishers, 1996. – P. 61–79.

11. Hyams J., Marcowitz J., Lerer T. et al. The natural history of corticosteroid therapy for ulcerative colitis in children // Clin. Gastroenterol. Hepatol. – 2006. – Vol. 4 (suppl. 9). – P. 1118–1123.

12. Keller R., Stoll R., Foerster E.C. et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial // Aliment. Pharmacol. Ther. – 1997. – Vol. 11. – P. 1047–1052.

13. Kolkman J., Mollmann H.W., Mollmann A.C. et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis // Drugs Today. – 2004. – Vol. 40. – P. 589–601.

14. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease // Gastroenterology. – 2006. – Vol. 130, N 3. – P. 935–939.

15. Mamula P., Marcowitz J.E., Baldassano R.N. Pediatric inflammatory bowel disease. Springer, 2007. – 662 p.

16. Marcowitz J., Grancher K., Kohn N. et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease // Gastroenterology.– 2000. – Vol. 119 (suppl. 4). – P. 895–902.

17. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs // N. Engl. J. Med. – 2005. – Vol. 353 (suppl. 16). – P. 1711–1723.

18. Stange E.F., Schreiber S., Folsch U.R. et al. Diagnostics and treatment of Crohn‘s disease – Results of an evidencebased consensus conference of the German Society for Digestive and Metabolic Diseases // Z. Gastroenterol. – 2003. – Vol. 41, N 1. – P. 19–20.

19. Travis S.P.L., Stange E.F., Lomann M. et al. European evidence based consensus on the diagnosis and management of Crohn‘s disease: current management // Gut.– 2006. – Vol. 55 (suppl. 1). – P. 16–35.